Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905841 | 0.83 | GLA (0.41) | — | |
| SCHEMBL14642680 | 0.80 | RAB9A (0.35) | RAB9ANPC1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL9911600 | 0.69 | NPC1 (0.32) | NPC1 | |
| SCHEMBL11385531 | 0.68 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL13150042 | 0.68 | ADORA2A (0.32) | ADORA2AADORA1 | |
| SCHEMBL671737 | 0.68 | TDP1 (0.32) | SMN1; SMN2HTT | |
| SCHEMBL21737413 | 0.67 | — | — | |
| SCHEMBL22409950 | 0.67 | — | — | |
| SCHEMBL27956808 | 0.67 | RAB9A (0.38) | RAB9ANPC1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL21718634 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870573-B1 | FUNCTIONALIZED AMINOTRIAZINES | LEADXPRO AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| WO-2020157069-A1 | AMINO HETEROCYCLIC COMPOUNDS AND USES THEREOF | NodThera Limited (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020083957-A1 | FUNCTIONALIZED AMINOTRIAZINES | LEADXPRO AG (CH) | 2020-04-30 | — | — | WO | disclosed |
| US-8193225-B2 | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090036451-A1 | Chemical inducers of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036451-A1 | Chemical inducers of neurogenesis | DCX, NES, GAP43 | RAB9A 2878/4885NPC1 1941/4885SMN1; SMN2 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.